Form 4: Akari Therapeutics CFO Acquires 6,277 ADSs

Akari Therapeutics' Interim CFO, Kameel D. Farag, acquired 6,277 American Depositary Shares representing restricted stock units.

Summary

• Interim CFO Kameel D. Farag acquired 6,277 American Depositary Shares (ADSs) of Akari Therapeutics Plc.
• These ADSs represent restricted stock units (RSUs), with each RSU representing the right to receive 2,000 Ordinary Shares.
• The transaction date for this acquisition was October 22, 2025.
• The reported price for the acquisition was $0.74 per ADS.
• Following this transaction, Kameel D. Farag beneficially owns 6,277 ADSs directly.
• The acquired RSUs are scheduled to vest on October 31, 2025.

Sentiment

Score: 7

Explanation: The acquisition of restricted stock units by an Interim CFO is generally a positive signal, indicating management's commitment and alignment with shareholder interests, though it's a compensation event rather than a direct cash investment.

Positives

• Interim CFO Kameel D. Farag increased his beneficial ownership in Akari Therapeutics by acquiring 6,277 American Depositary Shares.
• The acquisition of restricted stock units aligns management's interests with shareholders, incentivizing long-term performance.

Future Outlook

The acquired restricted stock units are scheduled to vest on October 31, 2025, indicating a future increase in the Interim CFO's vested equity and continued alignment with the company's performance.

Industry Context

Insider acquisitions, particularly of restricted stock units, are a common form of executive compensation designed to align management incentives with long-term company performance and shareholder value in the biotechnology and pharmaceutical sectors.

Comparison to Industry Standards

• The grant of restricted stock units to an Interim CFO is a standard practice in the biotechnology industry for executive compensation, comparable to similar equity incentive programs at companies like Biogen Inc. or Regeneron Pharmaceuticals, Inc., which often use stock-based awards to retain talent and incentivize performance.
• The specific value and vesting schedule would need to be compared against peer group compensation disclosures for a more detailed assessment of its competitiveness within the industry.

Related Party Transactions

• Acquisition of 6,277 American Depositary Shares (representing restricted stock units) by Interim CFO Kameel D. Farag from Akari Therapeutics Plc.

Stakeholder Impact

• Shareholders: Increased alignment of management's interests with shareholders due to equity compensation, potentially fostering confidence.
• Employees: Standard equity compensation practices can positively impact executive morale and retention, contributing to stable leadership.

Next Steps

• Vesting of the 6,277 American Depositary Shares on October 31, 2025.

Key Dates

Recommendation

The acquisition of restricted stock units by the Interim CFO is a positive signal of management's alignment with the company's future, but it is a compensation event rather than a direct market purchase. Without additional financial or operational updates, this single Form 4 filing primarily reinforces a 'hold' stance, as it doesn't fundamentally alter the company's investment thesis but rather confirms standard executive incentive practices.

Keywords

Akari Therapeutics, AKTX, Form 4, Insider Transaction, Restricted Stock Units, ADS, CFO, Equity Compensation